Heart Failure Challenge in T2DM

被引：0
|
作者：
Elmaraghi, Osama
机构：
来源：
EUROPEAN HEART JOURNAL SUPPLEMENTS | 2021年 / 23卷 / 0D期
关键词：
Heart failure; SGLT2i;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] SIGNIFICANCE OF PLASMA TGF-β1 LEVEL DETECTION IN PATIENTS WITH T2DM WITH HEART FAILURE
    Sun, Yunjing
    Miao, Bo
    Cao, Yabing
    Cui, Jiangman
    Da, Yingxiao
    Qi, Liping
    Zhou, Song
    JOURNAL OF MEDICAL BIOCHEMISTRY, 2024, 43 (05) : 704 - 710
  • [2] The Effect of SGLT2 Inhibitor Dapagliflozin on Serum Levels of Apelin in T2DM Patients with Heart Failure
    Berezin, Alexander A.
    Fushtey, Ivan M.
    Berezin, Alexander E.
    BIOMEDICINES, 2022, 10 (07)
  • [3] The safe use of metformin in heart failure patients both with and without T2DM: A cross-sectional and longitudinal study
    Chowdhury, Gina
    Carland, Jane E.
    Kumar, Shaun
    Olsen, Nick
    Graham, Garry
    Kumarasinghe, Gayathri
    Hayward, Christopher S.
    Greenfield, Jerry R.
    Macdonald, Peter
    Day, Richard O.
    Stocker, Sophie L.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (08) : 2603 - 2613
  • [4] Effect of Obesity & T2DM on Cardiac Strain in Youth
    Haley, Jessica E.
    Gao, Zhiqian
    Khoury, Philip
    Stewart, Stephanie N.
    Madsen, Nicolas L.
    Kimball, Thomas R.
    Dolan, Lawrence M.
    Urbina, Elaine M.
    CIRCULATION, 2017, 135
  • [5] Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events
    Towiargi, Ruba
    Fetyani, Lama
    Aljahdali, Naila
    Alnofeie, Adnan
    Alnoamy, Yahya
    Ghandorah, Reham
    Abduljawad, Abrar
    Alharbi, Njood
    Alghanmi, Alanoud
    AlButi, Hala
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (12)
  • [6] Insulin resistance and metabolic flexibility as drivers of liver and cardiac disease in T2DM
    Colosimo, Santo
    Mitra, Sandip Kumar
    Chaudhury, Tirthankar
    Marchesini, Giulio
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 206
  • [7] MANAGEMENT OF T2DM IN 2017 Clinically relevant results from cardiovascular outcome trials
    Holman, Rury R.
    NATURE REVIEWS ENDOCRINOLOGY, 2018, 14 (02) : 67 - 68
  • [8] Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology
    Wang, Anzhu
    Li, Zhendong
    Zhuo, Sun
    Gao, Feng
    Zhang, Hongwei
    Zhang, Zhibo
    Ren, Gaocan
    Ma, Xiaochang
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [9] Meta-Analysis on the Safety and Cardiorenal Efficacy of SGLT2 Inhibitors in Patients Without T2DM
    Li, Lu-Feng
    Ding, Liang-Liang
    Zhan, Ze-Lin
    Qiu, Mei
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [10] The challenge of acute decompensated heart failure
    Zannad, Faiez
    Adamopoulos, Chris
    Mebazaa, Alexandre
    Gheorghiade, Mihai
    HEART FAILURE REVIEWS, 2006, 11 (02) : 135 - 139
12345